These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 28107585)

  • 1. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
    Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
    Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
    Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
    Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
    Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
    Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
    J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
    Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ
    BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
    Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
    World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis.
    Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK
    Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire.
    Blake A; Smith JE
    JAMA Netw Open; 2021 Aug; 4(8):e2119092. PubMed ID: 34342652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
    Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
    Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Major M; Del Valle S; Cotler SJ; Dahari H
    PLoS One; 2015; 10(8):e0135901. PubMed ID: 26295805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
    Stone J; Martin NK; Hickman M; Hellard M; Scott N; McBryde E; Drummer H; Vickerman P
    PLoS One; 2016; 11(5):e0156213. PubMed ID: 27224423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium.
    Matheï C; Bourgeois S; Blach S; Brixko C; Mulkay JP; Razavi H; Robaeys G
    Acta Gastroenterol Belg; 2016; 79(2):227-32. PubMed ID: 27382943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.
    Lanièce Delaunay C; Klein MB; Godin A; Cox J; Kronfli N; Lebouché B; Doyle C; Maheu-Giroux M
    Int J Drug Policy; 2023 Jun; 116():104026. PubMed ID: 37075626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the Impacts of Prevention and Treatment Interventions on Hepatitis C Among People Who Inject Drugs in China.
    Fang K; Wang HL; Lin Y; Li S; Wu J
    Infect Dis Ther; 2023 Apr; 12(4):1043-1055. PubMed ID: 36894824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.
    Scott N; McBryde E; Vickerman P; Martin NK; Stone J; Drummer H; Hellard M
    BMC Med; 2015 Aug; 13():198. PubMed ID: 26289050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.